Mozenavir

Structural formula
General
Non-proprietary name	Mozenavir
other names	[4 R (4 α , 5 α , 6 β , 7 β )] - hexahydro-5,6-dihydroxy-1,3-bis [((3-aminophenyl) methyl) -4,7-bis (phenylmethyl) -2 H -1,3-diazepin-2-one] ( IUPAC )
Molecular formula	C 33 H 36 N 4 O 3
External identifiers / databases
CAS number 174391-92-5 PubChem 154044 Wikidata Q63390512
Drug information
Drug class	Protease inhibitors
properties
Molar mass	536.68 g · mol -1
safety instructions
GHS hazard labeling no classification available
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Mozenavir (also DMP-450 ) is a drug from the group of HIV protease inhibitors that was developed by Gilead Sciences . As the active ingredient showed no significant advantages over conventional HIV protease inhibitors, development was discontinued.

pharmacology

Mozenavir binds very tightly to the active site of the HIV protease. This prevents the processing of viral polyprotein precursors.

literature

Analytics:

• RD Vickery, MB Maurin, in: Journal of Pharmaceutical and Biomedical Analysis 1999 , 20 , 385-388.
• Grubb MF, Robinson CA, White SJ, Krauthauser CL, Shum L., in: Journal of Chromatography B 1996 , 678 , 303-308.

Synthesis:

• M. Patel, LT Bacheler et al., In: Bioorg. Med. Chem. Lett. 1998 , 8 , 823-828.

Pharmacology:

• PYS Lam, Y.Ru, PK Jadhav, PE Aldrich et al., In: J. Med. Chem. 1996 , 39 , 3514-3525.

Individual evidence

1. ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !